-- Scientific presentations on cladribine tablets include analysis on durability of NEDA (no evidence of disease activity) status and safety analysis with up to 10 years of follow-up data in some patients
Post hoc analysis of Phase III CLARITY study data recently published in Multiple Sclerosis Journal showed statistically significant reduction in brain atrophy in patients on a short course of investigational Cladribine Tablets over two years compared with patients receiving placebo
site contains medical information that is intended for residents of the
United States only and is not meant to substitute for the advice
provided by a medical professional. Always consult a physician if you
have health concerns. Use and access of this site is subject to the
This site contains information that is intended for US residents only.
Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada